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ABSTRACT
Introduction: While the care of HIV-positive patients,
including the detection and management of
comorbidities, has historically been provided in HIV
specialist outpatient clinics, recent years have seen a
greater involvement of non-HIV specialists and general
practitioners (GPs). The aim of this study is to
determine whether patients would prefer to see their
GP or HIV physician given general symptoms, and to
understand what aspects of care influence their
preferences.
Methods/analysis: We have developed and piloted a
discrete choice experiment (DCE) to better understand
patients’ preferences for care of non-HIV-related acute
symptoms. The design of the DCE was informed by
our exploratory research, including the findings of a
systematic literature review and a qualitative study.
Additional questionnaire items have been included to
measure demographics, service use and experience of
non-HIV illnesses and quality of life (EQ5D). We plan
to recruit 1000 patients from 14 HIV clinics across
South East England. Data will be analysed using
random-effects logistic regression and latent class
analysis. ORs and 95% CIs will be used to estimate
the relative importance of each of the attribute levels.
Latent class analysis will identify whether particular
groups of people value the service attribute levels
differently.
Ethics/dissemination: Ethical approval for this study
was obtained from the Newcastle and North Tyneside
Research Ethics Committee (reference number 14/NE/
1193). The results will be disseminated at national and
international conferences and peer-reviewed
publications. A study report, written in plain English,
will be made available to all participants. The Patient
Advisory Group will develop a strategy for wider
dissemination of the findings to patients and the
public.
INTRODUCTION
The number of people with HIV accessing
services in the UK continues to rise.3 While
mortality rates have dramatically improved as
a result of increasingly effective antiretroviral
treatment, they remain higher than in the
general population.4 Increased survival, com-
bined with later age at diagnosis, has resulted
in a disproportionate growth in the propor-
tion of older individuals accessing care.5
Strengths and limitations of this study
▪ This is the first study to use a discrete choice
experiment (DCE) to investigate HIV-positive
patients’ preferences for service delivery, thereby
involving service users in the design of future ser-
vices in a way that is robust and easy to interpret.
▪ Recruitment will take place across 14 different
sites including areas of high and low HIV preva-
lence and at sites with differing patient character-
istics, thereby allowing comparison of
preferences across different demographic
groups. Recruiting sites include HIV clinics in
London, Brighton and across the Kent, Surrey
and Sussex network to ensure representation of
patients who access different types of HIV clinics
(eg, multicentre and single-centre clinics and
smaller, rural clinics), and clinics with different
links to general practice (eg, Brighton which has
a locally enhanced service offering HIV-specific
training to general practitioners (GPs)). The
research benefits from a multidisciplinary collab-
oration of HIV clinicians (HIV doctor, nurse and
pharmacist), health economists, health service
researchers, statisticians, NHS commissioners, a
GP and patient representatives.
▪ The attributes and levels have been chosen
based on the findings of a systematic review and
qualitative research to identify which aspects of
care are most important to patients. To ensure
the research can realistically inform the future
design of services, we have selected attributes
and levels which are modifiable and can be deli-
vered within the context of the current
Department of Health Policy and British HIV
Association Guidelines.1 2
▪ The design of the questionnaire requires partici-
pants to make a decision on what they might do,
given a scenario, not what they have performed;
a limitation of the methodology.
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Complications due to opportunistic infections and
malignancies associated with HIV are now rare in suc-
cessfully treated individuals.6 7 However, diseases not his-
torically associated with HIV, but which are well
recognised as complications of ageing, including cardio-
vascular disease, bone mineral density loss, cancer, cog-
nitive decline, and hepatic and renal dysfunction, are
increasingly identiﬁed. These comorbidities (deﬁned as
the presence of more than one distinct condition in an
individual)8 appear to be occurring more frequently
and at an earlier age in HIV-positive individuals than in
HIV-negative populations.9–15 Older age and comorbid-
ities are associated with polypharmacy and an increased
risk of drug–drug interactions, which may lead to
reduced efﬁcacy of antiretroviral therapy.16–18
The care of HIV-positive individuals has historically
been provided within specialist HIV clinics. Little is
known about where HIV-positive individuals would
prefer to access care for non-HIV-related acute symp-
toms. However, HIV specialists may not have the neces-
sary experience to manage and treat these symptoms or
comorbidities and a different model of care may be pref-
erable from a clinical and patient perspective. Over
recent years, alternative models of care have been sug-
gested,19–21 such as combined clinics including one or
more specialist in addition to the HIV clinician;22 HIV
specialists adopting another specialist role (eg, with a
special interest in renal or liver disease)23 and dedicated
clinics for enhanced screening for comorbidities.24
However, these models have been developed in the
absence of an evidence base and without consideration
of patients’ preferences. At a more strategic level, the
recent NHS Five Year Forward Review emphasises the
need for closer working relationships between primary
and secondary care organisations.25 Thus, while it would
appear that care arrangements for people living with
HIV need to and are likely to radically alter over the
next decade, the signiﬁcant question of ‘how’ they
should change, and whether changes would be wel-
comed from a patient perspective, remains.
To date, there has been very little research assessing
patients’ preferences for the delivery of healthcare
among people with HIV. The systematic review suggested
that valued aspects of care among HIV-positive indivi-
duals can be grouped into seven main themes: a good
healthcare professional–patient relationship, HIV spe-
cialist knowledge, continuity of care, ease of access to
services, access to high-quality information and support,
effective coordination between HIV specialists and other
healthcare professionals, and involvement in decisions
about their treatment and care.26 There is currently no
other study which has quantitatively captured patient
preferences for healthcare in HIV-positive individuals in
this way.
Involving patients in decisions about their care
increases satisfaction with services, and improves attend-
ance and adherence to treatment thereby improving
health outcomes.27 Good management of chronic
disease, including the management of comorbidities, is
essential for the well-being of patients and reduces costs
for the NHS.25 28 29 This study represents a ﬁrst step
towards developing a coherent, evidence-based model
for the future management of HIV.
AIMS
The overall aim of the study is to determine whether
patients would prefer to see a general practitioner (GP)
or HIV physician given general symptoms, and to under-
stand what aspects of care inﬂuence their preferences.
Speciﬁc objectives are:
1. To determine the relative importance of different
service attributes to people living with HIV.
2. To determine which measurable patient-related
factors (including age, gender, ethnic group, sexual
preference, quality of life and experience of other
health conditions) inﬂuence preferences.
METHODS AND ANALYSIS
A discrete choice experiment (DCE)30 will be con-
ducted to better understand HIV-positive patients’ pre-
ferences for their healthcare in relation to where they
would choose to seek care given general symptoms.
DCEs have long been used in health economics as a
method for assessing patients’ preferences regarding
healthcare.31 This method is based on the premise that
healthcare services can be described in terms of their
attributes or characteristics and that an individual’s
evaluation, and therefore the choice of healthcare
service, is based on these attributes. The key to assessing
the relative preference for each attribute level is to gen-
erate a series of choices in a way in which respondents
are required to ‘trade them off’ against each other. For
example, a person could choose to see an HIV physician
rather than a GP, but they may have to wait longer to see
them. In this situation, the trade-off is between the type
of healthcare provider seen (HIV physician or GP) and
the waiting time.
Choice of attributes and levels
The DCE uses a ‘labelled’ design, where the labels refer
to choosing to go to the GP or an HIV clinic. The DCE
attributes and associated levels were determined based
on in-depth exploratory work, conducted as part of this
NIHR funded research (Research for Patient Beneﬁt).
A systematic literature review was initially conducted to
identify which aspects of healthcare are most important
to people living with HIV. Subsequently, 12 focus groups
consisting of a total of 74 patients were conducted with
HIV-positive patients across South East England. Groups
were quota sampled to ensure representation of younger
and older individuals (<50 and ≥50 years), people from
African and non-African communities, men who have
sex with men, and heterosexual men and women.
Participants were asked about their experiences of HIV
and non-HIV healthcare services. Focus groups were
2 Youssef E, et al. BMJ Open 2016;6:e008549. doi:10.1136/bmjopen-2015-008549
Open Access
group.bmj.com on August 17, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
audio-recorded and transcribed verbatim. Anonymous
transcripts were analysed using a framework approach to
establish the attributes and levels to be included in the
DCE.
Following the exploratory phase, a comprehensive list
of service attributes and levels for the DCE was produced.
A process of selecting and reﬁning these followed.
Decisions on the ﬁnal attributes and levels chosen from
this list were made by the multidisciplinary Steering
Group. Candidate attributes were prioritised if they could
potentially be modiﬁed. For example, ‘trust’ emerged as
being of particular importance to people with HIV;
however, this was excluded from the DCE design on the
basis that it is not readily amenable to intervention.
However, as a way of trying to incorporate this into an
attribute which could be modiﬁed, how many times the
participant had seen the healthcare provider in the previ-
ous year was included as an attribute in the ﬁnal question-
naire. The other attributes included in the ﬁnal DCE
were the healthcare professionals’ expertise in managing
general medical problems, HIV-speciﬁc expertise, ability
to refer the patient on to other services, availability of
appointments, how quickly appointments are made avail-
able and level of access to the patient information. The
healthcare professionals’ expertise in managing general
medical problems was the only ﬁxed attribute, which
means that the answers for this particular attribute did
not vary. This allowed the participant to understand that
the GP was a generalist with general knowledge, whereas
the HIV clinician was a specialist healthcare professional
and did not therefore have the same level of generalist
knowledge as a GP. The attributes and levels used in the
ﬁnal DCE are summarised in table 1.
Each of the DCE questions are framed in the same
way, so participants are presented with a hypothetical
scenario where they are asked to imagine that they have
woken up with a symptom such as a headache, fever,
rash, diarrhoea or abdominal pain. Given this scenario,
they are then asked to look at the attributes and levels of
each clinic and place a tick under the clinic they would
prefer to visit. These symptoms were chosen on the basis
of an audit of 50 sets of patient notes looking at the
most common reasons for walk-in or telephone triage
HIV emergency appointment requests by patients experi-
encing a new symptom that could be easily managed by
a non-HIV specialist. The results will therefore not only
indicate the relative importance of service attribute, but
rather will give an indication of how a GP service will
have to look in order for HIV-positive patients to attend
with a new, acute symptom.
Table 1 Attributes and levels used in the final DCE
Attribute GP levels HIV clinic—levels
The person you see is skilled at managing many
general medical problems
▸ Yes ▸ No
The person you see has the ability to refer you
on
to another healthcare professional, if required
▸ Yes, to any specialist doctor ▸ Yes, but only to your GP
▸ Yes, to any specialist doctor
How quickly you will be seen ▸ The same day
▸ The next day
▸ In 7 days
▸ In 14 days
▸ The same day
▸ The next day
▸ In 7 days
▸ In 14 days
An appointment out of usual working hours
if you would like it
▸ Not available
▸ Yes, 8:00 to 20:00 7 days a
week
▸ Yes, Monday to Friday 17:00–
20:00
▸ Yes, Saturday 8:00—mid-day
▸ Not available
Whether you have seen the healthcare
professional before
▸ No never
▸ Yes, once in the last year
▸ Yes, twice in the last year
▸ Yes, more than twice in the last
year
▸ No never
▸ Yes, once in the last year
▸ Yes, twice in the last year
▸ Yes, more than twice in the last
year
The type of person you see ▸ A GP with specialist HIV training
▸ A GP without specialist HIV
training
▸ An HIV consultant doctor
▸ A doctor training to specialise in
HIV
▸ An HIV specialist pharmacist
▸ An HIV specialist nurse
The level of information the person has access to ▸ All your medical records,
including your HIV details
▸ All your medical records, except
your HIV details
▸ All your medical records,
including your HIV details
▸ Just your HIV medical records
DCE, discrete choice experiment; GP, general practitioner.
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Early drafts of the DCE questionnaire were developed
and reviewed by the multidisciplinary research team. The
DCE was piloted three times with a total of 28
HIV-positive people recruited through community orga-
nisations, to ascertain patient acceptability and under-
standing. The questionnaires were revised following each
pilot study. Data from the ﬁnal pilot were analysed to look
for dominance in each attribute and level to ensure that
the questions were neutral and did not lead participants
to choose one service over another. An overview of the
DCE development process can be seen in ﬁgure 1. The
initial DCE questionnaire was generated using an orthog-
onal approach with zero priors, and set to 24 choice tasks
given the number of questions and 21 df in the design.
The ﬁnal design used a Bayesian D-efﬁcient approach;
the results of a pilot study consisting of 28 HIV-positive
people were used to inform the priors.
The number of attributes and levels chosen resulted
in a total number of 24 possible choices/questions. To
limit the number of questions/time burden on
participants, these questions have been split into 2
blocks of 12 and each participant will be asked to com-
plete one block picked at random. Assigning attributes
and levels to each block is performed by rotating each
option to ensure a balance in each block. To reduce the
impact of ‘learning effects’, there are two versions of
each block; both containing the same questions but in
reverse order.
Demographic questions containing items on age,
gender, sexuality, ethnicity, highest qualiﬁcation and
working status, GP service use, whether GP is aware of
HIV status and sexuality, self-reported clinical informa-
tion (including HIV treatment status, current and
nadir CD4, and year diagnosed with HIV) and self-
report of any current comorbidities have also been
included to understand whether preferences differ
depending on measurable patient characteristics. A
further ﬁve questions from the EQ5D-3L health ques-
tionnaire32 have been included to assess the quality of
life (ﬁgure 2).
Figure 1 Development of the discrete choice experiment.
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SAMPLE SIZE AND POWER
Sample size calculations for DCE experiments cannot be
calculated before the number of attributes and levels has
been decided unless there is sufﬁcient information.
However, there is doubt about the relevance of sample
size calculation in this methodology, because differences
in the strength of preferences for attributes are not always
expected. Since sufﬁcient information is lacking, a power
calculation was not performed. However, previous studies
using DCE methodology typically include 300–400 parti-
cipants.33 We have therefore set our recruitment target at
1000 participants; 500 completing ‘block 1’ question-
naires and 500 completing ‘block 2’ questionnaires
which is beyond the target needed to power the study.
This sample size will enable us to compare preferences
for services between different demographic groups.
Clinic throughputs and rates of attendance indicate
that more than 15 000 potentially eligible service users
will attend participating sites over a 6-month period.
Previous uptake of questionnaire-based research at these
sites suggests that at least 50% of eligible patients
approached will complete and return the questionnaire.
ADMINISTRATION AND ANALYSIS OF THE QUESTIONNAIRE
This study will be conducted in 14 HIV clinics across the
Kent, Surrey and Sussex Clinical Research Network, and
London. This will increase the generalisability of the
ﬁndings, as recruitment will take place in areas of high
and low HIV prevalence, rural and urban settings with
different models of HIV clinics (eg, multicentre and
single-centre clinics), in areas with and without
enhanced GP services and in areas with varying patient
demographics.
The questionnaire is anonymous and patients will
therefore not be required to complete any information
that could disclose their identity. All clinical information
is obtained by self-report by the patient and medical
notes will not be accessed. The location of questionnaire
completion will be recorded on all questionnaires to
assess differences in patient preference depending on
where the patient attends for HIV care.
IDENTIFICATION AND RECRUITMENT OF PATIENTS
Patients will be asked to conﬁrm their eligibility for the
study by conﬁrming they:
Figure 2 EQ5D-3L questions
included in the final discrete
choice experiment.
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▸ are aged 16 or over and
▸ have been diagnosed with HIV for at least 1 year.
Questionnaires and study materials are available in
English and French. Patients attending HIV clinics at
participating sites will be recruited in a variety of ways, as
described below.
▸ Patients recruited at their HIV clinic will be given verbal
study information by their clinical team, research nurse
or study dedicated researcher. Those expressing an
interest in taking part will be asked two screening ques-
tions in order to determine eligibility and (if applicable)
will be given the study questionnaire to complete.
Participants will be encouraged to complete the ques-
tionnaire in the clinic and once completed, to return it
to a box in the clinic area to maintain anonymity.
Patients who express a preference to complete the ques-
tionnaire online will be directed to it via a Quick
Response code (a type of matrix barcode) or a web
address, which will take them directly to the online
version of the questionnaire. Patients identiﬁed by the
clinical team who have previously provided written
consent to receive information about research studies by
email will be sent an email invitation by the research
team. This will include study information and a link to
the questionnaire.
▸ Posters will be put up in participating HIV clinics.
These posters will include study information, screen-
ing questions and information about how to access the
questionnaire. The online version of the questionnaire
will ask the participant which clinic they attend for
their HIV care from a drop-down list of participating
clinics, and this will allow questionnaires completed
online to also be traceable to a particular clinic.
▸ Study cards (business card size) will be available at
each clinic’s reception area. They will provide infor-
mation about how to access the questionnaire online.
DATA ANALYSIS
Data will be entered directly by one of the study
researchers into Microsoft Access, and 10% will be
checked by a second researcher. A pragmatic decision
was made that if the error rate exceeded 1%, then
further veriﬁcation by a second researcher would be
undertaken. Data will be imported into SPSS V.20 and
frequency distributions will be used to check for outliers.
The data will be stored on NHS computers within the
study team organisations and will be password protected.
The responses to the DCE questionnaires will be ana-
lysed using conditional logit and latent class models
(LCM); the latter allows for serial correlations in responses
and a formal assessment of preference heterogeneity. The
LCM groups respondents into classes that have similar pre-
ferences and in so doing, identiﬁes participant character-
istics associated with particular group membership. All of
the main effects parameters will be assumed to be alterna-
tive speciﬁc, meaning that respondents could value an
attribute differently depending on whether it related to a
GP appointment or HIV-clinic appointment. The data will
be analysed using STATAV.13.1 and NLOGIT V.5.
Results of this study will inform HIV-positive patients’ pre-
ferences for future care models. The analysis of preferences
by demographic group will ensure that all patients’ prefer-
ences are represented and will allow healthcare models to
be tailored to meet the needs of these patient groups.
DISSEMINATION
There will be no formal written consent process, as
consent will be implied by completion of the question-
naire. Patients will be assured that their answers are con-
ﬁdential. They will be asked to conﬁrm their eligibility
for the study by answering two screening questions.
Participants will be provided with a brief description of
the study and instructions for completing the question-
naire, including an example DCE question on the ques-
tionnaire itself. Contact details of the study researcher
will be provided. The risks to patients of completing this
anonymous questionnaire are minimal. However, should
patients wish to discuss issues that arise during this
research, they will be directed to speak with their usual
HIV doctor or nurse who will ensure that appropriate
support services are made available.
A study report, written in plain English, will be made
available to all participants. Submission of an abstract to
the British HIV Association conference and publication
in a peer-reviewed HIV journal will follow. The Patient
Advisory Group will develop a strategy for wider dissem-
ination of the ﬁndings to patients and the public.
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